Clinical trial
FR901228 in Treating Patients With Hematologic Cancer
NCT00024180 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00024180 |
|---|---|
| Title | FR901228 in Treating Patients With Hematologic Cancer |
| Official title | A Phase I Study of Depsipeptide in Selected Hematologic Malignancies (NSC 630176) |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Drug |
| Interventions | romidepsin |
| Start date | Jan 1, 2002 |
| Completion | Aug 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: